The UK thinks weight loss drugs could ease unemployment. Experts say that's a fantasy

Weight loss drugs like Wegovy and Ozempic are seen as groundbreaking in medicine. In the UK, the government wishes to use them to aid the unemployed in returning to work, potentially saving money on healthcare. The Health Secretary emphasized their potential to change lives, reduce NHS burden, and address work absenteeism due to obesity. Obesity costs the NHS £11 billion annually and contributes to an average of four extra sick days per year, affecting the economy.

To combat this, a five-year trial of the weight loss drug Mounjaro, or tirzepatide, is being funded in collaboration with the manufacturer Eli Lilly to study participants' life quality and employment impacts. However, healthcare professionals have raised concerns, arguing the health system is already under strain and further steps to prevent obesity are required. 

At least 29% of adults and 15% of children in England are obese. Obesity ranks as the second leading cause of preventable death in England and a risk factor for multiple diseases. The British Prime Minister has advocated for innovative approaches to alleviate pressure on the national healthcare system, involving weight loss drugs.

Nevertheless, specialists warn of the systemic overload and the necessity for comprehensive solutions. Experts argue drug treatments only address symptoms, not causes. The challenge lies in altering societal habits towards healthier foods amidst the prevalence of processed and fast foods. Policies could include taxing unhealthy foods, restricting marketing, serving healthier food in schools, and increasing regulations for nutritious meals. 

Changing an entire food system is complex but necessary to address obesity affecting a third of British adults. Various solutions across different sectors aim to tackle this widespread issue, though there is no singular solution to solve obesity.